Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Northeast Agricultural University, Harbin, People's Republic of China.
Microbiol Spectr. 2022 Dec 21;10(6):e0320722. doi: 10.1128/spectrum.03207-22. Epub 2022 Oct 26.
Intestinal microbiota dysbiosis is a well established characteristic of ulcerative colitis (UC). Regulating the gut microbiota is an effective UC treatment strategy. Berberine (BBR), an alkaloid extracted from several Chinese herbs, is a common traditional Chinese medicine. To establish the efficacy and mechanism of action of BBR, we constructed a UC model using healthy adult shorthair cats to conduct a systematic study of colonic tissue pathology, inflammatory factor expression, and gut microbiota structure. We investigated the therapeutic capacity of BBR for regulating the gut microbiota and thus work against UC in cats using 16S rRNA genes amplicon sequencing technology. Our results revealed that dextran sulfate sodium (DSS)-induced cat models of UC showed weight loss, diarrhea accompanied by mucous and blood, histological abnormalities, and shortening of the colon, all of which were significantly alleviated by supplementation with BBR. A 16S rRNA gene-based microbiota analysis demonstrated that BBR could significantly benefit gut microbiota. Western blot, quantitative PCR, and enzyme-linked immunosorbent assays (ELISAs) showed that in DSS-induced cat models, the expression of the inflammatory factors was increased, activating the JAK2/STAT3 signaling pathway, and treatment with BBR reversed this effect. The myosin light chain (MLC) phosphorylation in the smooth muscle of the intestines is associated with motility of inflammation-related diarrhea in cats. This study used gut flora analyses to demonstrate the anti-UC effects of BBR and its potential therapeutic mechanisms and offers novel insights into the prevention of inflammatory diseases using natural products. Ulcerative colitis (UC) is common in clinics. Intestinal microbiota disorder is correlated with ulcerative colitis. Although there are many studies on ulcerative colitis in rats, there are few studies on colitis in cats. Therefore, this study explored the possibility of the use of BBR as a safe and efficient treatment for colitis in cats. The results demonstrated the therapeutic effects of BBR on UC based on the state of the intestinal flora. The study found BBR supplementation to be effective against dextran sulfate sodium (DSS)-induced colitis, smooth muscle damage, and gut microbiota dysbiosis.
肠道微生物失调是溃疡性结肠炎(UC)的一个特征。调节肠道微生物是一种有效的 UC 治疗策略。黄连素(BBR)是从几种中草药中提取的生物碱,是一种常见的中药。为了确定 BBR 的疗效和作用机制,我们使用健康成年短毛猫构建了 UC 模型,对结肠组织病理学、炎症因子表达和肠道微生物结构进行了系统研究。我们使用 16S rRNA 基因扩增子测序技术研究了 BBR 调节肠道微生物从而对抗猫 UC 的治疗能力。我们的结果表明,葡聚糖硫酸钠(DSS)诱导的猫 UC 模型表现出体重减轻、腹泻伴粘液和血液、组织学异常和结肠缩短,这些都被 BBR 的补充显著缓解。基于 16S rRNA 基因的微生物分析表明,BBR 可以显著改善肠道微生物群。Western blot、定量 PCR 和酶联免疫吸附试验(ELISA)显示,在 DSS 诱导的猫模型中,炎症因子的表达增加,激活了 JAK2/STAT3 信号通路,而 BBR 的治疗逆转了这种作用。肠道平滑肌的肌球蛋白轻链(MLC)磷酸化与猫炎症相关腹泻的运动有关。本研究使用肠道菌群分析证明了 BBR 的抗 UC 作用及其潜在的治疗机制,并为使用天然产物预防炎症性疾病提供了新的见解。溃疡性结肠炎(UC)在临床上很常见。肠道菌群紊乱与溃疡性结肠炎有关。虽然有很多关于大鼠溃疡性结肠炎的研究,但关于猫结肠炎的研究很少。因此,本研究探讨了 BBR 作为一种安全有效的猫结肠炎治疗药物的可能性。研究结果基于肠道菌群的状态,证明了 BBR 对 UC 的治疗作用。研究发现,BBR 补充剂对葡聚糖硫酸钠(DSS)诱导的结肠炎、平滑肌损伤和肠道微生物失调有效。
Biochem Biophys Res Commun. 2024-2-5
Naunyn Schmiedebergs Arch Pharmacol. 2025-6-26
Pharmaceuticals (Basel). 2025-1-31
Crohns Colitis 360. 2024-11-28
Front Pharmacol. 2023-10-24
Evid Based Complement Alternat Med. 2022-4-19